Zhejiang Wild Wind Pharmaceutical Co., Ltd. was founded in 1996 and is affiliated to Wild Wind Group with a registered capital of 75 million yuan. The company is located in the Beijiang industrial zone ,Geshan Town, Dongyang City, Zhejiang Province, next to Zhuyong Expressway. The production area covers an area of more than 200 acres.
Taking pharmaceutical intermediates as the starting development cornerstone, the company has basically completed the product structure adjustment in the direction of pharmaceutical raw materials and biopharmaceuticals. The company is specialized in the R & D and production of high barrier medicine and biomedicine. It has established the core drug R & D technology platform of semi fermentation and semi synthesis technology platform and multi chiral drug technology platform. It has DOPA series products represented by methyldopa, fenjing series products represented by caspofungin, and statin series products represented by rosuvastatin calcium Technology.
The company mainly sells products abroad, and its sales network is spread throughout Europe, America, Japan, Canada, India, Brazil, etc., among which the sales of methyldopa APIs account for more than 60% of the world market.
The company has more than 340 employees, of which 35% are with high and intermediate technical titles, and more than 53% are graduates from colleges and secondary schools. The company has advanced production equipment, perfect public engineering system, complete chemical detection and gas, liquid chromatography, infrared spectrometer and other instruments, which can meet the needs of product production.
After more than 20 years of market trials and tribulations, Yefeng pharmaceutical has formed an enterprise staff team with excellent R & D, production, operation and management. It has carried out extensive and close technical cooperation and exchanges with East China University of science and technology, Zhejiang University, Zhejiang University of technology, Shenyang Institute of chemical industry, Sichuan University and other universities and scientific research institutions, and has made extensive and close technical cooperation and exchanges with Mitsubishi pharmaceutical in Japan, China and the United States in Hangzhou Huadong Pharmaceutical Co., Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd. and other well-known enterprises at home and abroad have established project cooperation.
The company has always adhered to the business policy of "rapid response, improving the core competitiveness of the enterprise; deepening the reengineering and pursuing the maximization of profits", fully implemented GMP management and EHS management system, and promoted the enterprise to integrate into the international market. The company has been awarded "China’s best corporate image AAA", "national high-tech enterprises", "Dongyang top 100 tax paying enterprises", "mayor’s science and Technology Innovation Award" and other honorary titles. Several products of the company have obtained domestic GMP certificate, Japanese PMDA certificate and EU EDQM certificate.
In 2019, the company hired Nobel laureate Erwin Nell and Russian Academy of Sciences Academician duxijin as technical consultants.